2014

Genta Announces Resignation of Dr. Betsy McCaughey from Board of Directors

    BERKELEY HEIGHTS, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Genta
 Incorporated (Nasdaq:   GNTA) announced today that Dr. Betsy McCaughey has
 submitted her resignation from the Company's Board of Directors. Dr.
 McCaughey has served on the Board since 2001.
     "As a noted author and health policy expert, we appreciate Betsy's
 commitment to mobilizing the response to reduce hospital infections from
 multiply resistant organisms, along with her increasing involvement in the
 national political discourse about healthcare reform," said Dr. Raymond P.
 Warrell, Jr., Chairman and Chief Executive Officer. "On behalf of all Genta
 Board members, we wish her success in these endeavors, and we are grateful
 for her years of counsel and service to our Company."
     About Genta
     Genta Incorporated is a biopharmaceutical company with a diversified
 product portfolio that is focused on delivering innovative products for the
 treatment of patients with cancer. The Company's research platform is
 anchored by two major programs: DNA/RNA-based Medicines and Small
 Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead
 compound from its DNA/RNA Medicines program. Genta is currently recruiting
 patients for a global Phase 3 trial of Genasense in patients with advanced
 melanoma. The leading drug in Genta's Small Molecule program is Ganite(R)
 (gallium nitrate injection), which the Company is exclusively marketing in
 the U.S. for treatment of symptomatic patients with cancer related
 hypercalcemia that is resistant to hydration. The Company has developed an
 oral formulation of the active ingredient in Ganite that is currently
 undergoing initial clinical trials as a potential treatment for diseases
 associated with accelerated bone loss. Genta is partnered with IDIS
 (www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R)
 are available on a "named-patient" basis in countries outside the United
 States. For more information about Genta, please visit our website at:
 www.genta.com.
     Safe Harbor
     This press release may contain forward-looking statements with respect
 to business conducted by Genta Incorporated. By their nature,
 forward-looking statements and forecasts involve risks and uncertainties
 because they relate to events and depend on circumstances that will occur
 in the future. Forward- looking statements include, without limitation,
 statements about:
     -- the Company's ability to obtain necessary regulatory approval for
        Genasense(R) from the U.S. Food and Drug Administration ("FDA") or
        European Medicines Agency ("EMEA");
     -- the safety and efficacy of the Company's products or product
        candidates;
     -- the Company's assessment of its clinical trials;
     -- the commencement and completion of clinical trials;
     -- the Company's ability to develop, manufacture, license and sell its
        products or product candidates;
     -- the Company's ability to enter into and successfully execute license
        and collaborative agreements, if any;
     -- the adequacy of the Company's capital resources and cash flow
        projections, and the Company's ability to obtain sufficient financing
        to maintain the Company's planned operations;
     -- the adequacy of the Company's patents and proprietary rights;
     -- the impact of litigation that has been brought against the Company and
        its officers and directors and any proposed settlement of such
        litigation; and
     -- the other risks described under Certain Risks and Uncertainties Related
        to the Company's Business, as contained in the Company's Annual Report
        on Form 10-K and Quarterly Report on Form 10-Q.
     The Company does not undertake to update any forward-looking
 statements. There are a number of factors that could cause actual results
 and developments to differ materially. For a discussion of those risks and
 uncertainties, please see the Company's Annual Report on Form 10-K for 2006
 and its most recent quarterly report on Form 10-Q.
     CONTACT:
     Brian Korb
     The Trout Group
     908-286-3980
     info@genta.com
 
 

SOURCE Genta Incorporated

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.